TY - JOUR
T1 - The key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity
AU - He, Yisheng
AU - Ma, Jiang
AU - Fan, Xiaoyu
AU - Ding, Liang
AU - Ding, Xinxin
AU - Zhang, Qing Yu
AU - Lin, Ge
N1 - Funding Information:
This work was supported by Research Grants Council of Hong Kong Special Administrative Region (GRF Project Nos. 14160817 and 14106318 to Ge Lin, China), and a grant from the National Institutes of Health (No. R01 GM082978 to Qing-Yu Zhang, USA). We thank Ms. Weizhu Yang for assistance with mouse breeding and genotyping analysis, Dr. Lei Yin and Dr. Xiangmeng Wu for assistance with analytical instruments, and Dr. Weiguo Han and Dr. Nataliia Kovalchuk for assistance with histological assays.
Publisher Copyright:
© 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
PY - 2021/12
Y1 - 2021/12
N2 - Pyrrolizidine alkaloids (PAs) are the most common phytotoxins with documented human hepatotoxicity. PAs require metabolic activation by cytochromes P450 to generate toxic intermediates which bind to proteins and form protein adducts, thereby causing cytotoxicity. This study investigated the role of the gut–liver axis in PA intoxication and the underlying mechanisms. We exposed mice to retrorsine (RTS), a representative PA, and for the first time found RTS-induced intestinal epithelium damage and disruption to intestinal barrier function. Using mice with tissue-selective ablation of P450 activity, we found that hepatic P450s, but not intestinal P450s, were essential for PA bioactivation. Besides, in RTS-exposed, bile duct-cannulated rats, we found the liver-derived reactive PA metabolites were transported by bile into the intestine to exert enterotoxicity. The impact of gut-derived pathogenic factors in RTS-induced hepatotoxicity was further studied in mice with dextran sulfate sodium (DSS)-induced chronic colitis. DSS treatment increased the hepatic endotoxin level and depleted hepatic reduced glutathione, thereby suppressing the PA detoxification pathway. Compared to RTS-exposed normal mice, the colitic mice displayed more severe RTS-induced hepatic vasculature damage, fibrosis, and steatosis. Overall, our findings provide the first mode-of-action evidence of PA-induced enterotoxicity and highlight the importance of gut barrier function in PA-induced liver injury.
AB - Pyrrolizidine alkaloids (PAs) are the most common phytotoxins with documented human hepatotoxicity. PAs require metabolic activation by cytochromes P450 to generate toxic intermediates which bind to proteins and form protein adducts, thereby causing cytotoxicity. This study investigated the role of the gut–liver axis in PA intoxication and the underlying mechanisms. We exposed mice to retrorsine (RTS), a representative PA, and for the first time found RTS-induced intestinal epithelium damage and disruption to intestinal barrier function. Using mice with tissue-selective ablation of P450 activity, we found that hepatic P450s, but not intestinal P450s, were essential for PA bioactivation. Besides, in RTS-exposed, bile duct-cannulated rats, we found the liver-derived reactive PA metabolites were transported by bile into the intestine to exert enterotoxicity. The impact of gut-derived pathogenic factors in RTS-induced hepatotoxicity was further studied in mice with dextran sulfate sodium (DSS)-induced chronic colitis. DSS treatment increased the hepatic endotoxin level and depleted hepatic reduced glutathione, thereby suppressing the PA detoxification pathway. Compared to RTS-exposed normal mice, the colitic mice displayed more severe RTS-induced hepatic vasculature damage, fibrosis, and steatosis. Overall, our findings provide the first mode-of-action evidence of PA-induced enterotoxicity and highlight the importance of gut barrier function in PA-induced liver injury.
KW - Cytochrome P450
KW - Gut–liver axis
KW - Inflammatory bowel disease
KW - Intestinal injury
KW - Liver injury
KW - Pyrrolizidine alkaloid
UR - http://www.scopus.com/inward/record.url?scp=85114992956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114992956&partnerID=8YFLogxK
U2 - 10.1016/j.apsb.2021.07.013
DO - 10.1016/j.apsb.2021.07.013
M3 - Article
AN - SCOPUS:85114992956
SN - 2211-3835
VL - 11
SP - 3820
EP - 3835
JO - Acta Pharmaceutica Sinica B
JF - Acta Pharmaceutica Sinica B
IS - 12
ER -